GlobalRPh Renal Dosing Masterv6.6
Source review / handoff

Rifaximin tablets (adults)

One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.

Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.

Share or print this source review

1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.

Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.

Clinical context remains essential

Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.

Check source scope before reading a dose

GlobalRPh RX List - XIFAXAN

Product / population
Adult oral rifaximin; selected renal evidence limitation, not a complete indication-specific course.
Renal method
Renal pharmacokinetics not studied in the selected label section.
Source revision
Source revision date not established in selected retrieval.
Retrieved
2026-09-07
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Rxlist

GlobalRPh RX List - XIFAXAN

Open original reference

GlobalRPh-hosted RX List · Adult oral rifaximin; selected renal evidence limitation, not a complete indication-specific course.

Renal method: Renal pharmacokinetics not studied in the selected label section.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Limited or unstudied renal evidence. Not studied does not mean no adjustment is required.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

Rifaximin pharmacokinetics have not been studied in patients with impaired renal function. The nearby no-adjustment statement in this source concerns hepatic impairment and local intestinal activity; it is not a directly studied renal or dialysis regimen. Match the intended indication and formulation before using an institutional recommendation.

RDM35-rxlist-rifaximin-617fd99576-C1 · Source locator: Renal impairment; dosage; warnings; pharmacokinetics, as identified in the selected retrieval.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/xifaxan-drug/
Retrieved
2026-09-07
Renal-function method
Renal pharmacokinetics not studied in the selected label section.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
43991349e5a49069bb578fd2d64528e591c0b1679b6835b98c9d04b3ab3d1f65

Document the clinical decision separately

This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.

GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.

Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=rifaximin&s1=RDM35-rxlist-rifaximin-617fd99576&h1=a0cb3d881f35f11e645b5ae39d940040c2536b23097e08ebeee675fa298547af